Anavex Life Sciences (AVXL) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Key strategic updates and pipeline progress

• Advancing oral small molecule therapies targeting Alzheimer's, Parkinson's, Rett syndrome, Fragile X, and schizophrenia, with regulatory submission to EMA planned by year-end for Alzheimer's.

• Blarcamesine demonstrated superior safety and efficacy versus antibody drugs in early Alzheimer's, with strong phase 2/3 data and ongoing open-label studies.

• Expanding rare disease franchise with new formulations for pediatric and swallowing-impaired patients, and planning further studies in Fragile X and other rare disorders.

• Schizophrenia candidate Anavex 3-71 in phase 2, with orphan designation for frontotemporal dementia and promising preclinical Alzheimer's data.

• Multiple upcoming catalysts: full phase 2/3 Alzheimer's data publication, EMA submission, open-label study updates, and phase 2 schizophrenia data readout.

Clinical and scientific highlights

• Sigma-1 receptor activation is the core mechanism, reducing cellular stress and enhancing autophagy, with genetic data supporting efficacy in patients with wild-type sigma-1.

• Oral blarcamesine offers upstream neuroprotection, slowing brain atrophy and showing resilience-building effects in the brain.

• Phase 2/3 Alzheimer's study met primary endpoint (ADAS-Cog13) and key secondary endpoints (CDR Sum of Boxes, CGI, MRI, and Aβ42/40 ratio), with numerically superior efficacy to donanemab.

• Compassionate use programs provide continued access to study drug for patients globally, with some on therapy for over four years.

• Rett syndrome studies show real-world improvements in mobility and seizure reduction, with strong investigator and patient support.

Financial and operational position

• $138.8 million in cash and no debt as of last quarter, supporting an estimated four years of operations at current burn rate.

• Strong patent protection through 2039 across all indications and geographies.

• Expanded leadership with biotech, big pharma, and regulatory veterans, including a former FDA neuro division member.

• Supported by advocacy groups and government grants, maintaining a modest burn rate.